United StatesÚltimas notícias

2025 delivered global conflict and political shockwaves - yet markets surged anyway.

Endeavour Silver Corp. (NYSE:EXK) reported full-year 2025 production of 6,486,661 ounces of silver and 37,164 ounces of gold, equivalent to 11.2 million silver equivalent ounces assuming an 80:1 ratio, representing a 48% increase from the prior year.

The Buckle (NYSE:BKE) reported robust sales performance for the five-week fiscal month ended January 3, 2026, a period encompassing the critical holiday shopping season.

Net sales increased 6.5% to $215.3 million from $202.1 million in the prior-year five-week period ended January 4, 2025.

CorMedix (NASDAQ:CRMD) reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, alongside initial fiscal 2026 guidance and program updates.

Menlo Park, California-based Personalis (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, reported unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.

Beverly Hills, California-based AXIL Brands (NYSE:AXIL) reported net sales of $8.1 million for its fiscal second quarter ended November 30, 2025, marking a 5.2% increase from the year-ago period.

Neogen (NASDAQ:NEOG) shares are in focus after the food and animal safety leader reported second-quarter revenue of $224.7 million, a 2.8% decline from the previous year.

TD SYNNEX (NYSE:SNX) today announced robust financial results for its fiscal fourth quarter ended November 30, 2025, demonstrating solid growth across key metrics.

Shares of software supply chain platform JFrog (NASDAQ:FROG) fell 4.7% in morning trading on January 8, 2026, as part of a broader market rotation out of the technology sector.

The decline came amid profit-taking in high-growth tech stocks following a strong recent rally, particularly in artificial-intelligence-related names.

Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.

The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.

Paramount (NASDAQ:PSKY) reaffirmed its $30-per-share cash offer for Warner Bros. Discovery on Thursday, resisting pressure to sweeten the deal even after WBD’s board dismissed the proposal as a risky "leveraged buyout."

Viking Therapeutics (NASDAQ:VKTX) finished enrolling patients in a clinical trial designed to test how different dosing schedules of its experimental obesity drug can help people keep weight off, a key step in its bid to compete with established giants in the metabolic space.